Profitability Metrics

Gross Margin
100.00%
Operating Margin
87.02%
Net Margin
86.13%

Efficiency Metrics

Revenue per Expense Ratio
7.70
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
0.6400000000

Balance Sheet Analysis

Current Ratio
0.13
Cash Ratio
0.38
Working Capital
$-30.88M
Debt to Equity
0.44
Debt to Assets
30.32%
Equity Ratio
69.19%

Cash Flow Analysis

Operating Cash Flow Ratio
248.06%
Free Cash Flow Ratio
248.06%
CapEx to Revenue
0.00%
Dividends Paid
$9.50M
Stock Buybacks
$56.31M
Total Shareholder Returns
$65.81M
Cash Position Change
-98.87%

Key Takeaways (2024 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased R&D investment by 100.00%

Detailed Growth Metrics

Core Performance

Revenue
380.29%
Net Income
334.17%
EPS
337.04%
Operating Income
336.59%

Operational Efficiency

R&D Expenses
100.00%
SG&A Expenses
747.16%
Operating Cash Flow
-22.97%
Free Cash Flow
-22.97%

Balance Sheet Health

Assets
-7.19%
Debt
189,565.86%
Book Value per Share
1.75%
Inventory
-100.00%

Shareholder Returns

Dividends per Share
-11.48%
Shares Outstanding
-1.56%

Long Term Trends

3Y Revenue/Share
-20.76%
5Y Revenue/Share
-23.41%
3Y Dividend/Share
-28.54%
5Y Dividend/Share
-29.28%